Toxicity Management in Squamous NSCLC

In this segment, the panel discusses the toxicity profile of CTLA-4-directed therapies and how experience with immune-modulating treatments has influenced their use in advanced squamous non-small cell lung cancer (NSCLC). Dr. Edward Kim describes the early experience with immune therapies, when management of potentially serious immune-related adverse events was concentrated among clinicians with specialized expertise. He emphasizes the importance of proactive monitoring and multidisciplinary collaboration to recognize and manage toxicities such as colitis, thyroiditis, hypophysitis, and pneumonitis. The panel notes that CTLA-4-related toxicities can be clinically significant and may require prompt intervention, while experience with PD-1 and PD-L1 inhibitors has increased clinicians' familiarity with immune-related adverse event management. Dr. Kim also highlights the importance of recognizing symptoms that may initially be attributed to other causes, such as distinguishing pneumonitis from disease progression. The discussion concludes with the role of education, clinical experience, laboratory monitoring, and multidisciplinary care in preparing clinicians to manage immune-related toxicities as newer immunotherapy-based approaches enter practice.